EP910 Non-epithelial ovarian cancer in tunisia: clinical presentation, treatment and outcome

Introduction/Background Non-epithelial ovarian tumors represent an heterogeneous group of rare ovarian cancer. The aim of this study was to describe the clinico-pathological features and treatment of those malignancies in a Tunisian single center. Methodology Medical records of 134 patients with non-epithelial ovarian tumors treated between 1980 and 2010 were reviewed. Data collected included clinical features, treatment modalities and prognostic indicators. Results Overall, 94 were germ cell tumors (70%) and 40 sex cord-stromal tumors (30%). Thirty-six (27%) had immature teratoma, 28 (21%) had dysgerminoma, 13 (10%) had mixed germ cell tumors, 12 (9%) had yolk sac tumor, 5 (4%) had embryonal carcinoma, 37 (27%) had adult granulose cell tumors, 2 (1.5%) had juvenile granulose cell tumors and one (0.5%) had leydig and sertoli cells tumor. Median age at diagnosis was 28 years (range 7–95). Mean age was 27 for immature teratoma, 18 for dysgerminoma, 21 for mixed germ cell tumors, 23 for yolk sac tumor, 13 for embryonal carcinoma, 52 for adult granulose cell tumors and 24 for juvenile granulose cell tumors. Ninety-four (70%) presented with abdominal mass and/or pain. Surgery was the first treatment for 99% (n=133) with fertility sparing management in 79%. FIGO staging was as follows: Stage I in 63% (n=84) (stage IC: 23% of stage I), stage II in 6% (n=8), stage III in 24% (n=32), and stage IV in 7% (n=10). Sixty-four (48%) received adjuvant chemotherapy. Median follow-up period was 45 months. The 5-year odds survival was 78%. Reccurence occurred in 18% (n=24).The 5-years disease free survival was 75%. Conclusion As it is usually unilateral and chemosensitive with high incidence in young women, fertility-sparing surgery with optimal staging should be the standard of care of non-epithelial ovarian cancer. Disclosure Nothing to disclose.